TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05640427
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same capacity of 0.9% normal saline was used in group C
Study: NCT05511948
Drug: DBI-102
Normalized name: BAG,ENTERAL DRAIN SET ENFIT #DBISO-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application on dorsal hand and upper volar arm
Study: NCT05511948
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive comparator
Study: NCT06186609
Drug: PD-1 inhibitor 200mg per three to four weeks, for one year
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction.
Study: NCT05188989
Drug: TPN171H 2.5mg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
Study: NCT05188989
Drug: TPN171H 5mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
Study: NCT05188989
Drug: TPN171H 10mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
Study: NCT05188989
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
Study: NCT04648020
Drug: Placebo Mucoadhesive Buccal Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05067335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo in a specified sequence during the treatment Period.
Study: NCT05309525
Drug: Lysteda 650 MG Oral Tablet
Normalized name: Lysteda 650 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
Study: NCT05849129
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose ascorbic acid delivered intravenously
Study: NCT06563518
Drug: Meridol
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothpaste
Study: NCT05819359
Drug: BIA 28-6156 10 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 28-6156 10 mg, once daily, oral administration.
Study: NCT05819359
Drug: BIA 28-6156 60 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 28-6156 60 mg, once daily, oral administration.
Study: NCT05819359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, oral administration.
Study: NCT06560333
Drug: Januvia® + Glifage XR® + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg
Study: NCT06560333
Drug: Forxiga® + Glifage XR® + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg
Study: NCT04747301
Drug: Dinoprostone 10mg (Propess)
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured.
Study: NCT06154590
Drug: Method(s)2 Attribution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)
Study: NCT06079983
Drug: JSKN003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously according to protocol.
Study: NCT06079983
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study: NCT06654193
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Saline Solution
Study: NCT05904717
Drug: Matching Placebo (B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once daily (QD) for period of 12 weeks
Study: NCT04695990
Drug: Wenyang Huoxue Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenyang Huoxue granules
Study: NCT04695990
Drug: Wenyang Huoxue placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
Study: NCT06010680
Drug: [14C]SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
Study: NCT06632080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
Study: NCT05745714
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous
Study: NCT05323656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05391555
Drug: Remifentanil Hydrochloride
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes. Pupillary measurements will be taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
Study: NCT06058091
Drug: RY_SW01 cell injection
Normalized name: phenylephrine tannate / pyrilamine tannate Oral Suspension [Ry-T-12]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer basic treatment with an injection of RY_SW01 cell solution
Study: NCT06058091
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment for SSc
Study: NCT06357104
Drug: Pravastatin Sodium 20 MG
Normalized name: pravastatin sodium 20 MG
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
Study: NCT06341335
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv, q3w
Study: NCT05006664
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment by study drug Doxorubicin in combination.
Study: NCT06564584
Drug: TLC-2716 Dose 1
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT06564584
Drug: TLC-2716 Dose 2
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT06564584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT05766605
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study: NCT05766605
Drug: Oxaliplatin, Leucovorin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions
Study: NCT04881760
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04881760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04769869
Drug: AZD4604 for inhalation via DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Study: NCT04769869
Drug: Placebo for AZD4604 for inhalation via DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10.
Study: NCT04769869
Drug: AZD4604 for inhalation via DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
Study: NCT05132829
Drug: Azithromycin 1 gram IV
Normalized name: azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
Study: NCT05132829
Drug: Cefazolin and indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative standard of care with cefazolin and indomethacin
Study: NCT04943679
Drug: Anti-PD-1/PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection for up to 2 years
Study: NCT04368819
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
Study: NCT06080555
Drug: Ferric Carboxymaltose Injection [Ferinject]
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
Study: NCT05772871
Drug: Huaiqihuang granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study: NCT05772871
Drug: Huaiqihuang Granule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study: NCT05270863
Drug: BRIMOCHOL™ PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single drop in each eye at a visit.
Study: NCT06194656
Drug: HER3 Monoclonal antibodies-Dose C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Study: NCT04681144
Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
Study: NCT05465304
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
Study: NCT06426979
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.
Study: NCT04682665
Drug: Icosapent Ethyl Oral Capsule
Normalized name: icosapent ethyl Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
Study: NCT06579846
Drug: Cytisinicline and exercise
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes.
Study: NCT06061692
Drug: Tongxinluo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
Study: NCT06579846
Drug: Cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same intervention as the experimental group without directed exercise prescription
Study: NCT03769688
Drug: Cervicovaginal secretions
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as arm descriptions
Study: NCT05732064
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
Study: NCT04454515
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline infusion
Study: NCT04863742
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained released dexamethasone, 0.4mg
Study: NCT04863742
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
Study: NCT03567694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05589454
Drug: Atorvastatin Calcium tablets 80mg
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Study: NCT05589454
Drug: Atorvastatin Calcium tablets 20mg
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Study: NCT05559099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules to match tecovirimat
Study: NCT06211712
Drug: Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
Study: NCT05918445
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05555212
Drug: QLH11811
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D.
Study: NCT05990686
Drug: Fentanyl injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~.
Study: NCT05363592
Drug: CT-L01 12.5/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet, 2 tablets at a time, oral administration
Study: NCT05411497
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06650384
Drug: Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
Study: NCT05223673
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
Study: NCT05223673
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
Study: NCT05790356
Drug: Fecal Microbial transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
Study: NCT06717360
Drug: AG2304T
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG2304T, QD, PO
Study: NCT06717360
Drug: AG2304R
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG2304R, QD, PO
Study: NCT04470024
Drug: INCMGA00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1
Study: NCT04743011
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
Study: NCT04743011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
Study: NCT05291650
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.
Study: NCT05790447
Drug: PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
Study: NCT05863455
Drug: mild sedation and analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation